Francesco Giorgino, MD, an investigator on the ACHIEVE-5 trial, offered a longer-term perspective on orforgliprons potential in an interview published by Medscape Medical News, noting that its small-molecule structure makes it significantly easier to manufacture than peptide-based GLP-1 drugs
Its primary route of elimination is metabolism following proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain, with excretion via urine and feces and roughly 3% of the dose excreted in urine as intact semaglutide
PubMed CrossRef Chen X, Zhao P, Wang W, et al
Identification of novel GH-regulated pathway of lipid metabolism in adipose tissue: A gene expression study in hypopituitary men
13,14 Intriguingly, emerging research proposes that GLP-1 RA treatments might hold the potential to treat addictive disorders, although this area remains under investigation
Suitable for all skin types, including sensitive skin